RB Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,119
Closed -$215K 189
2025
Q2
$215K Sell
3,119
-13,142
-81% -$894K 0.05% 171
2025
Q1
$1.13M Sell
16,261
-3,031
-16% -$250K 0.26% 71
2024
Q4
$1.66M Sell
19,292
-951
-5% -$103K 0.38% 61
2024
Q3
$2.41M Buy
20,243
+1,571
+8% +$210K 0.56% 45
2024
Q2
$2.67M Buy
18,672
+1,508
+9% +$200K 0.66% 40
2024
Q1
$2.2M Buy
17,164
+3,526
+26% +$420K 0.58% 42
2023
Q4
$1.41M Buy
+13,638
New +$1.35M 0.4% 60

Other funds holding NVO

RB Capital Management's NVO Position: Q3 2025 in Review

RB Capital Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,119 shares — an estimated $215K sold.

RB Capital Management first reported a position in NVO in Q4 2023 and held it in 7 quarters. The position peaked at $2.67M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • RB Capital Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • RB Capital Management sold 3,119 Novo Nordisk shares in Q3 2025, an estimated $215K.
  • RB Capital Management first reported a position in Novo Nordisk in Q4 2023 and held it in 7 quarters.
  • RB Capital Management's Novo Nordisk position peaked at $2.67M in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on RB Capital Management's 13F filing for Q3 2025, filed 21 Oct 2025.